A B S T R A C T In conscious dogs intravenously infused somatostatin (3.3 tg per min for 1 h) caused prompt and sustained declines in mean plasma insulin and glucagon, even during alanine infusion and intraduodenal casein hydrolysate feeding; plasma glucose declined, but not significantly. 6.7 pig per min of somatostatin significantly lowered pancreatoduodenal vein glucagon and insulin within 2.5 min and profoundly suppressed their secretion throughout the infusion. Consistent bihormonal suppression occurred at rates as low as 24 ng per kg per min, but was variable at 12 and 2.4 ng per kg per min. When somatostatin-induced (3.3 lig per min) hypoglucagonemia was corrected by exogenous glucagon, hyperglycemia occurred. In dogs with long-standing insulin-requiring alloxan diabetes 3.3 ,ug per min of somatostatin suppressed glucagon to 55 pg per ml throughout the 30-min infusion and lowered glucose by 36.4±6.1 mg per dl, about 1 mg per dl per min. Glucagon suppression was maintained despite alanine infusion, and glucose, which rose 29 mg per dl during alanine infusion without somatostatin, declined 58 mg per dl in the somatostatin-treated diabetic dogs despite alanine. Continuous infusion of somatostatin for 24 h in five insulin-requiring alloxan-diabetic dogs suppressed glucagon and lowered glucose significantly, usually to below normal.
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It is concluded that in normal dogs pharmacologic doses of somatostatin virtually abolish insulin and glucagon secretion in the basal state and during hyperaminoacidemia. Hyperglycemia occurs during somatostatin-induced insulin lack only if hypoglucagonemia is corrected. Somatostatin suppresses glucagon in diabetic dogs and lowers their plasma glucose approximately 1 mg per dl per min, even when the gluconeogenic substrate alanine is abundant. Glucagon suppression can be
INTRODUCTION
It has recently been reported that the hypothalamic polypeptide somatostatin (1) is a potent inhibitor of insulin and glucagon secretion in humans, in baboons, and in the perfused dog pancreas (2) (3) (4) (5) (6) . The per min for 1 h, caused a decline in mean plasma insulin and glucagon within 5 min, the first postinjection sample point ( Fig. 1) . Insulin fell from 7.6±0.8 AU per ml to 5.1±0.5 at 5 min (P < 0.02) and to a nadir of 3.7±0.3 at 45 min (P < 0.001), rising to 14±2.5 .U per ml 30 min after the end of the infusion. Glucagon declined from 56±8 pg per ml at zero time to 43±4 at 5 min (N. S.) and reached a nadir of 32±2 at 30 min (P < 0.01). When the infusion was discontinued glucagon rose sharply to 96±20 pg per ml. The mean molar ratio of insulin to glucagon, not shown in Fig. 1 , did not change significantly from the mean basal value of 3.6+ 0.3 at any point during the infusion.
Mean plasma glucose declined slightly from 89.4±4.9
mg per dl to a nadir of 78.9±3.6 at 30 min, but the changes in mean glucose concentration were not statistically significant.
Effects of somatostatin on pancreaticoduodenal vein insulin and glucagon. To determine whether or not the changes in islet hormone concentration observed in the peripheral plasma represent simultaneous or sequential secretory changes, five normal conscious dogs with indwelling pancreaticoduodenal vein catheters received somatostatin intravenously at a rate of 6.7 Ag per min for 30 min, and samples were obtained at more frequent intervals (Fig. 2) . The mean glucagon level declined from 246±24 pg per ml to 123±32 pg per ml at 1 min (P < 0.02) and gave "zero" readings in the assay. When reassayed in the more sensitive system, a nadir of 32±14 at 20 min was recorded (P < 0.001 cally significant change in the mean insulin level first appeared 2.5 min after the start of the infusion (P < 0.01). Suppression was maintained throughout the remainder of the infusion, the minimal mean insulin level being 2.1±0.9 iAU per ml at 20 and 30 min. A rebound to or above basal levels followed the termination of the infusion and persisted for the ensuing 30 min.
In three of the five dogs, glucagon secretion was suppressed before insulin, while in the other two the hormones declined simultaneously. Glucose declined from a zero time average of 91.0±8.9 mg per dl to 80.0±11.5 at the end of the infusion (N.S.).
The effect of somatostatin on plasma insulin, glucagon, and glucose during alanine infusion in normal dogs. Alanine is a gluconeogenic precursor (10) known to stimulate glucagon secretion (11) . To Table I . A sustained suppression of both hormones was observed at the 24 ng per kg per min rate in all three dogs, but was not statistically significant because of the small sample size. At both of the lower rates, the responses were less consistent and more transient and not statistically significant. The mean glucose level at every point was significantly greater than in dogs receiving the same dose of somatostatin without glucagon, the maximum difference in mean glucose levels between groups being 55 mg per dl. This difference is all the more notable when one considers that insulin was not suppressed by somatostatin during glucagon infusion (Fig. 5) . When glucagon was discontinued, the continued infusion of somatostatin was accompanied by a decline in mean glucagon of almost 200 pg per ml during the ensuing 45 min and mean glucose fell 33 mg per dl during this period, about 0.7 mg per dl per min. At a higher infusion rate of somatostatin, 6.7 ig per min, the same dose of glucagon caused hyperglycemia averaging 155±5 mg per dl at 20 min. Effects of somatostatin in diabetic dogs. To determine if glucagon suppression favorably influences glucose regulation in diabetes, the effect of somatostatin was studied in five dogs with long-standing alloxan diabetes. In random order 2 wk apart the dogs received a 30-min intravenous infusion of either somatostatin (3.3 isg per min) or a saline control (Fig. 6 ). In the dogs receiving somatostatin glucagon declined from a mean of 114±14 pg per ml at zero time to 80±10 in 5 min and reached a nadir of 55±9 at 20 min (P < 0.02). Glucose declined from a preinfusion average of I (Fig. 7) . In the control -^i ; studies, the infusion of alanine was accompanied by a > , -_ i_ rise in glucagon from 98±11 pg per ml to a peak of c'-142 > 140±12. During somatostatin infusion glucagon remained suppressed, averaging 55±13 pg per ml at the To evaluate the effects of more prolonged glucagon suppression upon diabetic hyperglycemia, somatostatin was infused at a rate of 3.3 sg in 0.3 ml of saline per min for 24 h in five dogs with insulin-requiring alloxan diabetes. Saline alone was infused as a control at the same rate during the preceding and the subsequent 24 h. Blood samples were obtained at the same time five times daily. The dogs received their usual insulin dose and their customary meal at 7 a.m. and 2:30 p.m. daily.
The individual results are shown in Fig. 8 . Glucagon averaged 167 pg per ml at the start of the somatostatin infusion at 7 a.m. By 9 a.m. it had declined to 75 pg per ml or less in every dog. At noon it ranged between 25 and 50 pg per ml, significantly below the 7 a.m. value and close to the sensitivity limits of the glucagon assay. All glucagon values during the somatostatin infusion were significantly less by paired t test than the corresponding levels at the same time on either the preceding or following day (P < 0.005).
Glucose levels, which averaged 214 mg per dl before the somatostatin infusion at 7 a.m., also declined in every dog after the fall in glucagon. At noon the glucose was below 100 mg per dl in four of the five dogs and remained below normal through 4:30 p.m. The glucose values during somatostatin infusion differed significantly by paired t test from the corresponding values on each of the preceding control days of saline infusion (P <0.01). A significant correlation between the glucagon and glucose levels was observed during the day of somatostatin therapy (r = 0.57, P <0.01). The uniform pattern of a declining glucagon level followed by a reduction in plasma glucose was in contrast to the irregular lability observed on the previous and subsequent days (Fig. 8) . DISCUSSION These studies in conscious dogs confirm earlier reports (2) (3) (4) (5) (6) (17) and, while it reduces the glucagon response to alanine, it does not block it (18) . Second (20) provide strong evidence that glucagon makes a contribution to glucose homeostasis, which on the basis of all data available in these studies, approximates 1 mg per dl per minute in the dog. If the decrease in glucose production resulting from the lack of glucagon were slightly greater than the decrease in glucose utilization resulting from the lack of insulin, the small decline in glucose concentration during somatostatin suppression would be explained.
Koerker et al. (6) calculate that in the baboon somatostatin infusion is accompanied by complete inhibition of hepatic glucose production. Simultaneous reduction in insulin and glucagon must decrease glucose turnover, just as simultaneous stimulation of the two hormones by arginine has been shown to increase glucose turnover as much as 70% above the basal (21) . Yet glucose concentration changes relatively little in these contrasting circumstances, suggesting that glucagonmediated input into and insulin-mediated outflow from the glucose pool must be similar. These studies provide new insight into glucagon's contribution to the hyperglycemia of diabetes. In the acute experiments in alloxan-diabetic dogs glucagon was suppressed by somatostatin to almost half of the basal levels in 30 min. The associated mean maximal glucose decline during those 30 min averaged 33 mg per dl, or about 1 mg per dl per min. And when glucagon returned to basal levels after termination of the infusion, the mean maximal rise in glucose from the nadir averaged 60 mg per dl during the ensuing hour, again about 1 mg per dl per min. Inasmuch as insulin could not have changed in these insulin-deficient dogs, the glucose changes may reflect the glucagon-mediated contribution to the hyperglycemia. Moreover, somatostatin prevented the alanine-induced rise in glucagon and maintained glucagon suppression at half basal levels. Instead of a 29 mg per dl mean maximal rise in glucose during alanine infusion, a mean maximal decline of 58 mg per dl was observed. The ability to suppress glucagon during hyperaminoacidemia may provide for the first time a means of correcting the paradoxical lowering of insulin-glucagon ratio caused by food (14) and amino acids (22) in severe diabetes without the need for additional meal-time insulin administration.
The 24-h somatostatin infusion experiments indicate that profound glucagon suppression can be uniformly maintained for at least 7.5 h in alloxan-diabetic dogs and that in most instances it reduced previously elevated and labile plasma glucose levels to a low normal range and, at least for the brief period of observation, seemed to maintain them there. A relationship between glucagon levels and glucose levels in diabetics with fixed insulin levels is suggested by the data. The pattern observed here, although limited to a single day, suggests that glucose levels are less labile when glucagon secretion is blocked and that sustained euglycemia, so difficult to achieve with insulin alone, may be possible if glucagon is concomitantly suppressed.
It remains to be determined if endogenous somatostatin is a physiologic regulator of the endocrine pancreas. LeBlanc, Anderson, Riggs, and Yen have shown that a single injection of 1 Ag can suppress glucagon and insulin in humans (23) . If, in fact, somatostatin is a physiologic inhibitor of growth hormone, thyroidstimulating hormone, insulin, and glucagon secretion, a role as a reducer of metabolic turnover rates can be envisioned.
